Hydrogel embedded oligodoxynucleotides as tolerognic adjuvant for subcutaneous immunotherapy

Reinhard Bredehorst; Thomas Grunwald; Cathy Léonard; Markus Ollert

Hydrogel embedded oligodoxynucleotides as tolerognic adjuvant for subcutaneous immunotherapy

Reinhard Bredehorst (Inventor)
, Thomas Grunwald (Inventor)
, Cathy Léonard (Inventor)
, Markus Ollert (Inventor)

Research output: Patent

Abstract

The present invention discloses novel hydrogel-based technologies and methods for subcutaneous immunotherapy of allergic and autoimmune diseases which allows tolerogenic modulation of human antigen-presenting cells (APCs) including dendritic cells and macrophages with CpG-ODN or GpC-ODN or GpB-ODN at tolerted dose levels.

Original language	English
IPC	WO 2019/076478
Publication status	Published - 24 Apr 2019

Cite this

@misc{b46ed6b230b941a8bdcc0a413dedc1d5,

title = "Hydrogel embedded oligodoxynucleotides as tolerognic adjuvant for subcutaneous immunotherapy",

abstract = "The present invention discloses novel hydrogel-based technologies and methods for subcutaneous immunotherapy of allergic and autoimmune diseases which allows tolerogenic modulation of human antigen-presenting cells (APCs) including dendritic cells and macrophages with CpG-ODN or GpC-ODN or GpB-ODN at tolerted dose levels.",

author = "Reinhard Bredehorst and Thomas Grunwald and Cathy L{\'e}onard and Markus Ollert",

year = "2019",

month = apr,

day = "24",

language = "English",

type = "Patent",

note = "WO 2019/076478",

}

TY - PAT

T1 - Hydrogel embedded oligodoxynucleotides as tolerognic adjuvant for subcutaneous immunotherapy

AU - Bredehorst, Reinhard

AU - Grunwald, Thomas

AU - Léonard, Cathy

AU - Ollert, Markus

PY - 2019/4/24

Y1 - 2019/4/24

N2 - The present invention discloses novel hydrogel-based technologies and methods for subcutaneous immunotherapy of allergic and autoimmune diseases which allows tolerogenic modulation of human antigen-presenting cells (APCs) including dendritic cells and macrophages with CpG-ODN or GpC-ODN or GpB-ODN at tolerted dose levels.

AB - The present invention discloses novel hydrogel-based technologies and methods for subcutaneous immunotherapy of allergic and autoimmune diseases which allows tolerogenic modulation of human antigen-presenting cells (APCs) including dendritic cells and macrophages with CpG-ODN or GpC-ODN or GpB-ODN at tolerted dose levels.

M3 - Patent

ER -

Hydrogel embedded oligodoxynucleotides as tolerognic adjuvant for subcutaneous immunotherapy

Abstract

Fingerprint

Cite this